- Home
- Products
- Customized ADCs
- CEACAM8
- Anti-CEACAM8 (Besilesomab)-MC-MMAF ADC
Anti-CEACAM8 (Besilesomab)-MC-MMAF ADC (CAT#: ADC-W-2206)
This ADC product is comprised of an anti-CEACAM8 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CEACAM8
- Alternative Names
- CEACAM8; carcinoembryonic antigen-related cell adhesion molecule 8; CGM6; CD66b; CD67 antigen; carcinoembryonic antigen CGM6; non-specific cross-reacting antigen NCA-95; carcinoembryonic antigen gene family member 6; CD67; NCA-95;
- Target Entrez Gene ID
- 1088
- Target UniProt ID
- P31997
- Overview
- Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) also known as CD66b (Cluster of Differentiation 66b), is a member of the carcinoembryonic antigen (CEA) gene family. Its main function is cell adhesion, cell migration, and pathogen binding.
- Overview
- Humanized Anti-CEACAM8 IgG1-kappa antibody, Besilesomab
- Generic name
- Besilesomab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IFNG (Crenezumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1229)
- Anti-RTN4 (Ozanezumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1745)
- Anti-ITGAV+ITGB3 (Etaracizumab)-MC-MMAF ADC (CAT#: ADC-W-2128)
- Anti-EGFR (Cetuximab)-SMCC-DM1 ADC (CAT#: ADC-W-2589)
- Anti-SLC3A2 (clone IGNX)-Mc-MMAF ADC (CAT#: ADC-W-550)
- Anti-CD19 (Taplitumomab paptox)-SMCC-DM1 ADC (CAT#: ADC-W-770)
- Anti-CTLA4 (Ticilimumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1008)
- Anti-S. epidermidis LTA (Pagibaximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2261)
- Anti-CD3E (Catumaxomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2273)
- Anti-CCR5 (PRO 140)-SMCC-DM1 ADC (CAT#: ADC-W-764)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2206. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Payload
Same Target
Same Linker
CAT# | Product Name | Linker | Payload |
ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2567 | Anti-MUC16 (Sofituzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
CAT# | Product Name | Linker | Payload |
ADC-W-2209 | Anti-CEACAM8 (Besilesomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2208 | Anti-CEACAM8 (Besilesomab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2207 | Anti-CEACAM8 (Besilesomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2204 | Anti-CEACAM8 (Besilesomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2205 | Anti-CEACAM8 (Besilesomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-517 | Anti-TM4SF1 ( clone v1.10)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-114 | Anti-CD33 (clone m2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.